Vimta Labs Limited Stock Price Today (NSE: VIMTALABS)
Vimta Labs Limited
Fundamental Score
Vimta Labs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vimta Labs Limited share price today is ₹598.45, down 2.85% on NSE/BSE as of 16 September 2026. Vimta Labs Limited (VIMTALABS) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹2.67K (Cr). The 52-week high for VIMTALABS share price is ₹851.00 and the 52-week low is ₹376.05. At a P/E ratio of 33.51x, VIMTALABS is currently trading below its industry average P/E of 39.78x. The company has a Return on Equity (ROE) of 18.55% and a debt-to-equity ratio of 0.01.
Vimta Labs Limited Share Price Chart — NSE/BSE Historical Performance
Vimta Labs Limited share price chart: -2.71% return over the past month. 52-week high ₹851.00, 52-week low ₹376.05.
Vimta Labs Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹615.05 | ₹619.10 | ₹580.00 | ₹598.45 | 2.87L (Cr) | |
| ₹637.90 | ₹642.00 | ₹613.00 | ₹616.00 | 1.21L (Cr) | |
| ₹635.80 | ₹635.80 | ₹623.25 | ₹629.60 | 75.01K (Cr) | |
| ₹625.10 | ₹641.25 | ₹625.10 | ₹634.95 | 1.05L (Cr) | |
| ₹625.00 | ₹638.75 | ₹617.35 | ₹628.15 | 1.76L (Cr) | |
| ₹642.20 | ₹647.70 | ₹622.00 | ₹625.80 | 1.87L (Cr) | |
| ₹636.00 | ₹644.65 | ₹633.15 | ₹640.65 | 1.10L (Cr) | |
| ₹655.45 | ₹657.00 | ₹631.05 | ₹635.65 | 2.19L (Cr) | |
| ₹664.00 | ₹672.00 | ₹650.00 | ₹652.25 | 3.07L (Cr) | |
| ₹666.65 | ₹666.65 | ₹644.00 | ₹655.35 | 3.01L (Cr) |
Vimta Labs Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹643.45 | ₹672.00 | ₹580.00 | ₹598.45 | -6.99% | |
| ₹605.05 | ₹675.00 | ₹605.05 | ₹643.45 | +6.35% | |
| ₹585.00 | ₹634.00 | ₹526.75 | ₹608.85 | +4.08% | |
| ₹474.00 | ₹610.00 | ₹451.55 | ₹587.55 | +23.96% | |
| ₹457.15 | ₹579.40 | ₹435.85 | ₹469.70 | +2.75% | |
| ₹397.00 | ₹489.90 | ₹391.80 | ₹457.15 | +15.15% | |
| ₹426.85 | ₹460.00 | ₹376.05 | ₹380.70 | -10.81% | |
| ₹442.00 | ₹511.80 | ₹418.80 | ₹452.05 | +2.27% | |
| ₹605.30 | ₹636.75 | ₹408.10 | ₹411.05 | -32.09% | |
| ₹613.00 | ₹648.95 | ₹577.00 | ₹605.30 | -1.26% | |
| ₹727.40 | ₹735.00 | ₹593.70 | ₹609.05 | -16.27% | |
| ₹711.80 | ₹774.70 | ₹661.80 | ₹725.40 | +1.91% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vimta Labs Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vimta Labs Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VIMTALABS across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (18.55%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (23.39%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (32.77%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (14.09% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (29.35% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (90.08x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.92)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹105.38 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
High Price-to-Book Ratio (7.02x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Limited Institutional Interest (FII+DII: 5.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Vimta Labs Limited vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Vimta Labs Limited with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Vimta Labs LimitedVimta Labs Limi...Selected✓ VIMTALABS • 524394 | 63.6/100 | ₹598.45₹598 | ₹2673.28₹2673.28 | 33.51Average 33.5 Average | 18.55%Good 18.55% Good | 23.39%Excellent 23.39% Excellent | 0.01Excellent 0.0 Excellent | 29.35%Excellent 29.35% Excellent | 14.09%Good 14.09% Good | 0.35% |
Syngene International LimitedSyngene Interna... SYNGENE • 539268 | 35.4/100 | ₹386.80₹387 | ₹15615.12₹15615.12 | 70.33Average 70.3 Average | 0.00%Poor 0.00% Poor | 8.43%Poor 8.43% Poor | 0.00Excellent 0.0 Excellent | -0.98%Poor -0.98% Poor | 11.35%Good 11.35% Good | 0.30% |
Indegene LimitedIndegene Limite... INDGN • 544172 | 57/100 | ₹586.35₹586 | ₹14101.72₹14101.72 | 35.09Average 35.1 Average | 13.94%Average 13.94% Average | 17.29%Good 17.29% Good | 0.00Excellent 0.0 Excellent | 23.02%Excellent 23.02% Excellent | 29.44%Excellent 29.44% Excellent | 0.39% |
Suven Life Sciences LimitedSuven Life Scie... SUVEN • 530239 | 11.4/100 | ₹357.50₹358 | ₹9437.75₹9437.75 | — — | -78.80%Poor -78.80% Poor | -78.35%Poor -78.35% Poor | 0.00Excellent 0.0 Excellent | — — | -12.00%Poor -12.00% Poor | 0.00% |
TAKE LimitedTAKE Limited... TAKE • 532890 | 31.2/100 | ₹15.99₹16 | ₹236.55₹236.55 | 18.59Average 18.6 Average | 42.11%Excellent 42.11% Excellent | 18.49%Good 18.49% Good | 0.00Excellent 0.0 Excellent | 15.08%Excellent 15.08% Excellent | -41.25%Poor -41.25% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 56.9/100 | ₹78.10₹78 | ₹164.67₹164.67 | 45.33Average 45.3 Average | 8.00%Poor 8.00% Poor | 9.96%Poor 9.96% Poor | 0.09Excellent 0.1 Excellent | 22.72%Excellent 22.72% Excellent | 151.69%Excellent 151.69% Excellent | 0.00% |
Bilcare LimitedBilcare Limited... BI • 526853 | 28.9/100 | ₹91.66₹92 | ₹147.94₹147.94 | 26.80Average 26.8 Average | 1.66%Poor 1.66% Poor | 5.56%Poor 5.56% Poor | 3.15Poor 3.1 Poor | 16.32%Excellent 16.32% Excellent | 3.33%Average 3.33% Average | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 24.6/100 | ₹16.30₹16 | ₹23.52₹23.52 | 19.47Average 19.5 Average | 3.38%Poor 3.38% Poor | 6.02%Poor 6.02% Poor | 0.16Excellent 0.2 Excellent | -6.68%Poor -6.68% Poor | -3.19%Poor -3.19% Poor | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 23.9/100 | ₹19.60₹20 | ₹13.94₹13.94 | 163.55Average 163.6 Average | 0.76%Poor 0.76% Poor | 1.39%Poor 1.39% Poor | 1.80Average 1.8 Average | -24.21%Poor -24.21% Poor | -28.62%Poor -28.62% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Limited share price15615.12 Cr
- Indegene Limited share price14101.72 Cr
- Suven Life Sciences Limited share price9437.75 Cr
- TAKE Limited share price236.55 Cr
- NOVELIX PHARMACEUTICALS LIMITE share price164.67 Cr
Vimta Labs Limited PE Ratio History
Historical price-to-earnings ratio for VIMTALABS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹14.93 | ₹605.30 | 40.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vimta Labs Limited Dividend History
Annual cash dividends paid by VIMTALABS — dividend yield 0.35%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹4.43 Cr |
| FY 2024 | ₹4.43 Cr |
| FY 2023 | ₹4.42 Cr |
| FY 2022 | ₹4.42 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Vimta Labs Limited Quarterly Performance
Latest quarterly metrics for VIMTALABS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
11.80%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
11.37%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
14.09%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
29.35%
Compounded annual net profit growth over 5 years
Vimta Labs Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VIMTALABS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vimta Labs Limited Financial Statements
Annual income statement, balance sheet and cash flow for Vimta Labs Limited (VIMTALABS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Vimta Labs Limited
About VIMTALABS (Vimta Labs Limited)
Vimta Labs Ltd is a pioneering force within the healthcare research, analytics, and technology landscape, providing a comprehensive suite of services that underpin the advancement ...of medical science and patient care. The company distinguishes itself through its commitment to rigorous scientific methodology, cutting-edge technologies, and a team of highly skilled professionals dedicated to driving innovation. From meticulously designed preclinical studies to expertly managed clinical trials and sophisticated analytical investigations, Vimta Labs serves as a strategic partner for biopharmaceutical companies, medical device manufacturers, and organizations navigating the complexities of healthcare product development. Its focus extends to ensuring the safety and efficacy of healthcare products, empowering its clients to bring innovative solutions to market with confidence. The capabilities of Vimta Labs span the entire healthcare product lifecycle, encompassing early-stage research, clinical development, and post-market surveillance. Employing advanced technologies in genomics, proteomics, and bioinformatics, the company extracts meaningful insights from complex data, accelerating drug discovery and personalized medicine approaches. Their analytical prowess extends to comprehensive quality control and regulatory compliance, helping clients to navigate the intricate web of industry regulations. By combining deep scientific expertise with sophisticated analytical tools, Vimta Labs contributes to informed decision-making, optimized product development strategies, and improved patient outcomes. Its commitment to rigorous testing and insightful data analysis makes it a valuable partner for businesses seeking to ensure the success of their healthcare products. Beyond traditional laboratory services, Vimta Labs embraces technological advancements to enhance its capabilities and deliver integrated solutions. The company leverages sophisticated data analytics platforms, artificial intelligence, and machine learning algorithms to extract valuable insights from large datasets, accelerating research and optimizing clinical trial design. By seamlessly integrating technology with its scientific expertise, Vimta Labs fosters innovation, drives efficiency, and provides its clients with a competitive edge. With a steadfast dedication to scientific excellence, technological innovation, and client satisfaction, Vimta Labs continues to be a trusted partner for companies seeking to transform healthcare through research, analytics, and advanced technology.
Company Details
Key Leadership
VIMTALABS Share Price: Frequently Asked Questions
What is the current share price of Vimta Labs Limited?
Vimta Labs Limited (VIMTALABS) trades at ₹598.45 on NSE and BSE. Market cap ₹2.67K (Cr). Educational data only.
What is the P/E ratio of Vimta Labs Limited?
Vimta Labs Limited has a P/E of 33.51x vs industry average 39.78x.
What is the Bull Run score for Vimta Labs Limited?
Vimta Labs Limited has a Bull Run score of 63.6/100 based on 25+ financial parameters.
Does Vimta Labs Limited pay dividends?
Vimta Labs Limited has a dividend yield of 0.35%. Past dividends don't guarantee future payments.
What is the ROE of Vimta Labs Limited?
Vimta Labs Limited has ROE of 18.55%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vimta Labs Limited?
Vimta Labs Limited has debt-to-equity of 0.01.
Is Vimta Labs Limited a good investment?
Bull Run gives Vimta Labs Limited a score of 63.6/100. This is not investment advice — consult a SEBI-registered advisor.